{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:05:10Z","timestamp":1780513510372,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","labmed.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.cll.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T06:30:47Z","timestamp":1504247447000},"page":"771-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Aaron C.","family":"Shaver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Seegmiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/leu.2012.216","article-title":"Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.cll.2017.07.005_bib2","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.cll.2017.07.005_bib3","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","article-title":"Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL","volume":"123","author":"Strati","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cll.2017.07.005_bib4","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cll.2017.07.005_bib5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","article-title":"Minimal residual disease in acute myeloid leukaemia","volume":"10","author":"Hourigan","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"10.1016\/j.cll.2017.07.005_bib6","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cyto.b.21272","article-title":"Assessment of minimal residual disease in myeloma and the need for a consensus approach","volume":"90","author":"Rawstron","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"10.1016\/j.cll.2017.07.005_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.12442","article-title":"Predicting relapse risk in childhood acute lymphoblastic leukaemia","volume":"162","author":"Teachey","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cyto.b.21239","article-title":"Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry","volume":"90","author":"Wood","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"10.1016\/j.cll.2017.07.005_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2016.09.006","article-title":"Monitoring minimal residual disease in acute leukemia: technical challenges and interpretive complexities","volume":"31","author":"Chen","year":"2017","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.cll.2017.07.005_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/sj.leu.2401364","article-title":"A\u00a0limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection","volume":"13","author":"Weir","year":"1999","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.cll.2017.07.005_bib12","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood.V98.8.2498","article-title":"Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry","volume":"98","author":"McKenna","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cll.2017.07.005_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/1042819031000151950","article-title":"Immunophenotypic analysis of hematogones (B-lymphocyte precursors) and neoplastic lymphoblasts by 4-color flow cytometry","volume":"45","author":"McKenna","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.cll.2017.07.005_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2004.05011.x","article-title":"Haematogones in the peripheral blood of adults: a four-colour flow cytometry study of 102 patients","volume":"126","author":"Kroft","year":"2004","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.cll.2017.07.005_bib15","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1309\/AJCP8G5RMTWUEMUU","article-title":"Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia","volume":"132","author":"Seegmiller","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.cll.2017.07.005_bib16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1309\/AJCPOOJRAVUN75GD","article-title":"B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model","volume":"143","author":"Shaver","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.cll.2017.07.005_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/ajcp\/102.2.231","article-title":"B-cell precursor bone marrow reconstitution after bone marrow transplantation","volume":"102","author":"Leitenberg","year":"1994","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2141.2000.02143.x","article-title":"Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease","volume":"110","author":"van Wering","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/cyto.b.20071","article-title":"Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children\u2019s oncology group","volume":"68","author":"Borowitz","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.leu.2403559","article-title":"Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection","volume":"19","author":"Gaipa","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1309\/7R6MU7R9YWJBY5V4","article-title":"Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia\/lymphoma: a single institution experience","volume":"127","author":"Chen","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.cll.2017.07.005_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/cyto.b.20408","article-title":"Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells","volume":"74","author":"Gaipa","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.cll.2017.07.005_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cyto.b.20516","article-title":"Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group","volume":"78","author":"Dworzak","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.cll.2017.07.005_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-62703-357-2_8","article-title":"Flow cytometric monitoring of residual disease in acute leukemia","volume":"999","author":"Wood","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.cll.2017.07.005_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A\u00a0complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.cll.2017.07.005_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cll.2017.07.005_bib27","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.leu.2403001","article-title":"Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children\u2019s Oncology Group study","volume":"17","author":"Borowitz","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.cll.2017.07.005_bib28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/cyto.b.21101","article-title":"Detection of minimal residual disease in pediatric acute lymphoblastic leukemia","volume":"84","author":"Gaipa","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"10.1016\/j.cll.2017.07.005_bib29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1309\/AJCP02RPVOKTNWEC","article-title":"Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry","volume":"132","author":"Muzzafar","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2017.07.005_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10428199409052682","article-title":"Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry","volume":"13","author":"Orfao","year":"1994","journal-title":"Leuk Lymphoma"},{"issue":"9102","key":"10.1016\/j.cll.2017.07.005_bib31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)10295-1","article-title":"Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia","volume":"351","author":"Coustan-Smith","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cll.2017.07.005_bib32","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2002-04-1130","article-title":"Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cll.2017.07.005_bib33","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.leu.2402736","article-title":"Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia","volume":"17","author":"Bj\u00f6rklund","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2002-01-0006","article-title":"Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cll.2017.07.005_bib36","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2017.07.005_bib37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/pbc.22944","article-title":"Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children\u2019s Oncology Group trial P9906","volume":"57","author":"Bowman","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.cll.2017.07.005_bib38","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cll.2017.07.005_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2403283","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse","volume":"18","author":"Coustan-Smith","year":"2004","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.cll.2017.07.005_bib40","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cll.2017.07.005_bib41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","article-title":"Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study","volume":"16","author":"Pui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.cll.2017.07.005_bib42","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2015-09-671131","article-title":"Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels","volume":"126","author":"Mullighan","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cll.2017.07.005_bib43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2011-01-333070","article-title":"High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia","volume":"118","author":"Leung","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cll.2017.07.005_bib44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00277-011-1285-1","article-title":"Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Zhao","year":"2012","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.cll.2017.07.005_bib45","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.cll.2017.07.005_bib46","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","article-title":"Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA","volume":"32","author":"Ribera","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cll.2017.07.005_bib47","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood.V128.22.2907.2907","article-title":"Experience with MRD testing in B-ALL by flow cytometry does not prevent interpretative discordance","volume":"128","author":"Keeney","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.cll.2017.07.005_bib48","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.cll.2017.07.005_bib49","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2017.07.005_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.cll.2017.07.005_bib51","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cll.2017.07.005_bib52","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/cncr.30031","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies","volume":"122","author":"Kantarjian","year":"2016","journal-title":"Cancer"},{"issue":"9967","key":"10.1016\/j.cll.2017.07.005_bib53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"224","key":"10.1016\/j.cll.2017.07.005_bib54","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T\u00a0cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"36","key":"10.1016\/j.cll.2017.07.005_bib55","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T\u00a0cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cll.2017.07.005_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/cyto.b.21482","article-title":"A\u00a0novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia\/lymphoma post anti-CD19 therapy","author":"Cherian","year":"2016","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271217300677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271217300677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T16:50:49Z","timestamp":1719420649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271217300677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0272271217300677"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2017.07.005","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2017.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}